查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586181

細胞再程式化市場：按技術、應用和最終用途分類 – 2025-2030 年全球預測

Cell Reprogramming Market by Technology (Episomal Reprogramming, mRNA Reprogramming, Sendai Virus-Based Reprogramming), Application (Research, Therapeutic), End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

細胞再程式化市場2023年估值為3.7559億美元，預計到2024年將達到4.1388億美元，複合年成長率為10.59%，到2030年將達到7.5992億美元。

細胞再程式化是指將成熟的特化細胞轉回具有分化成任何類型細胞能力的多功能細胞的過程。這種創新方法在再生醫學和生物技術中具有重要意義，因為它在治療退化性疾病、組織修復和藥物發現方面具有巨大潛力。對 KEYWORD 的需求源於其超越成人和胚胎幹細胞使用限制的能力，為研究和治療應用提供更通用、更合乎道德的替代方案。最終用戶包括專注於再生醫學和個人化醫療解決方案的製藥公司、研究機構和醫療機構。

主要市場統計
基準年[2023] 37559萬美元
預測年份 [2024] 41388萬美元
預測年份 [2030] 75992萬美元
複合年成長率（%） 10.59%

細胞再程式化市場的成長主要是由幹細胞研究投資的增加、CRISPR等基因工程技術的進步以及對慢性疾病有效治療解決方案的持續需求所推動的。組織工程和 3D 生物列印領域的創新正在將再程式化的範圍從基礎研究擴展到臨床環境，創造出令人興奮的應用。機會在於開發可擴展、高效且安全的初始化技術，克服當前的限制，例如低效率和潛在的基因組不穩定性。建議與領先的生物技術公司和學術機構建立策略夥伴關係和合作，以釋放此類機會。

然而，再程式化過程的高成本、道德問題、監管障礙和技術複雜性等限制構成了重大挑戰。與基因組修飾相關的潛在安全問題和與多功能細胞相關的腫瘤發展風險也阻礙了市場。應對這些挑戰需要集中創新，以提高初始化效率和安全分析，同時確保遵守不斷變化的法規。

需要研究和創新的領域包括開發非整合初始化方法、改進直接初始化方法以最小化中間多功能階段以及增強自動初始化系統的穩健性。隨著細胞再程式化市場的成熟，向更有針對性的方法和個性化應用的轉變可能會成為其發展的特徵，這使其成為擅長應對複雜情況的公司的一項重大投資，並提供了成長潛力。

市場動態：揭示快速發展的細胞再程式化市場的關鍵市場洞察

細胞再程式化市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 在再生醫學和疾病建模的應用
    • 採用尖端技術進行幹細胞研究與治療
    • 藥物發現和藥物開發活動的增加
  • 市場限制因素
    • 細胞再程式化高成本
  • 市場機會
    • 細胞重編程的進展
    • 對細胞再程式化的重大投資
  • 市場挑戰
    • 細胞再程式化的技術問題與局限性

波特五力：駕馭細胞再程式化市場的策略工具

波特的五力框架是了解細胞再程式化市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解細胞再程式化市場的外部影響

外部宏觀環境因素在塑造細胞再程式化市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解細胞再程式化市場的競爭狀況

對細胞再程式化市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV定位矩陣單元再程式化市場供應商績效評估

FPNV定位矩陣是評估細胞再程式化市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，以規劃細胞再程式化市場的成功之路

細胞再程式化市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 在再生醫學和疾病模型的應用
      • 引進幹細胞研究和治療的先進技術
      • 增加藥物發現和開發活動
    • 抑制因素
      • 細胞再程式化成本高昂
    • 機會
      • 細胞再程式化的進展
      • 對細胞再程式化的重大投資
    • 任務
      • 細胞再程式化的技術問題與局限性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章細胞再程式化市場：依技術分類

  • 遊離重編程
  • mRNA重編程
  • 用仙台病毒重新編程

第7章細胞再程式化市場：依應用分類

  • 調查
  • 治療性的

第8章細胞再程式化市場：依最終用途

  • 生物技術和製藥公司
  • 醫院/診所
  • 研究/學術機構

第9章美洲細胞再程式化市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太細胞再程式化市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲細胞再程式化市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • ALSTEM Inc.
  • Applied Biological Materials Inc.
  • Axol Bioscience Ltd.
  • Bit Bio Ltd.
  • Bristol Myers Squibb Company
  • CD Biosynsis
  • Cell Reprogramming & Therapeutics LLC
  • Cellular Reprogramming, Inc.
  • Creative Bioarray
  • DefiniGEN Limited
  • Fujifilm LImited
  • Lonza AG
  • Merck KGaA
  • Mogrify Limited
  • REPROCELL Inc.
  • Stemnovate Limited
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
  • TOKIWA-Bio inc.,
  • Allele Biotechnology and Pharmaceuticals, Inc.
Product Code: MRR-F927BA462855

The Cell Reprogramming Market was valued at USD 375.59 million in 2023, expected to reach USD 413.88 million in 2024, and is projected to grow at a CAGR of 10.59%, to USD 759.92 million by 2030.

Cell reprogramming refers to the process of reverting mature, specialized cells into pluripotent stem cells, which have the ability to differentiate into any cell type. This innovative approach is crucial in regenerative medicine and biotechnology due to its vast potential for treating degenerative diseases, tissue repair, and drug discovery. The necessity for cell reprogramming arises from its ability to transcend the limitations of adult stem cells and embryonic stem cell use, providing a more versatile and ethical alternative for research and therapeutic applications. End-users span pharmaceutical companies, research laboratories, and medical institutions focusing on regenerative medicine and personalized healthcare solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 375.59 million
Estimated Year [2024] USD 413.88 million
Forecast Year [2030] USD 759.92 million
CAGR (%) 10.59%

Market growth for cell reprogramming is primarily driven by increasing investments in stem cell research, advancements in genetic engineering technologies such as CRISPR, and the ongoing demand for efficient treatment solutions for chronic conditions. Innovations in tissue engineering and 3D bioprinting are creating exciting applications, expanding the reprogramming scope beyond basic research into potential clinical environments. Opportunities lie in developing scalable, efficient, and safe reprogramming techniques that overcome current limitations such as low efficiency and potential genomic instability. Strategic partnerships and collaborations with leading biotech firms and academic institutions are recommended to unlock these opportunities.

However, limitations such as high costs, ethical concerns, regulatory hurdles, and the technical complexity of reprogramming processes pose significant challenges. The market is also hindered by potential safety issues related to genomic modifications and the tumorigenic risks associated with pluripotent cells. Addressing these challenges requires focused innovations in enhancing reprogramming efficiency and safety profiling while ensuring compliance with evolving regulations.

Areas ripe for research and innovation include developing non-integrative reprogramming methods, improving direct reprogramming to minimize intermediate pluripotent stages, and enhancing the robustness of automated reprogramming systems. As the cell reprogramming market matures, a shift towards more targeted approaches and personalized applications will likely characterize its evolution, offering substantial growth potential for companies adept at navigating its complexities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell Reprogramming Market

The Cell Reprogramming Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Applications in regenerative medicine and disease modeling
    • Adoption of advanced technologies in stem cell research and therapies
    • Rise in drug discovery and drug development activities
  • Market Restraints
    • High cost of cell reprogramming
  • Market Opportunities
    • Advancements in cellular reprogramming
    • Significant investments in cell reprogramming
  • Market Challenges
    • Technical issues and limitations of cell reprogramming

Porter's Five Forces: A Strategic Tool for Navigating the Cell Reprogramming Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell Reprogramming Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell Reprogramming Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell Reprogramming Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell Reprogramming Market

A detailed market share analysis in the Cell Reprogramming Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell Reprogramming Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell Reprogramming Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cell Reprogramming Market

A strategic analysis of the Cell Reprogramming Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cell Reprogramming Market, highlighting leading vendors and their innovative profiles. These include ALSTEM Inc., Applied Biological Materials Inc., Axol Bioscience Ltd., Bit Bio Ltd., Bristol Myers Squibb Company, CD Biosynsis, Cell Reprogramming & Therapeutics LLC, Cellular Reprogramming, Inc., Creative Bioarray, DefiniGEN Limited, Fujifilm LImited, Lonza AG, Merck KGaA, Mogrify Limited, REPROCELL Inc., Stemnovate Limited, Takara Bio Inc., Thermo Fisher Scientific, Inc., TOKIWA-Bio inc.,, and Allele Biotechnology and Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Cell Reprogramming Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Episomal Reprogramming, mRNA Reprogramming, and Sendai Virus-Based Reprogramming.
  • Based on Application, market is studied across Research and Therapeutic.
  • Based on End-Use, market is studied across Biotechnology & Pharmaceutical Companies, Hospitals & Clinics, and Research & Academic Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Applications in regenerative medicine and disease modeling
      • 5.1.1.2. Adoption of advanced technologies in stem cell research and therapies
      • 5.1.1.3. Rise in drug discovery and drug development activities
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of cell reprogramming
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in cellular reprogramming
      • 5.1.3.2. Significant investments in cell reprogramming
    • 5.1.4. Challenges
      • 5.1.4.1. Technical issues and limitations of cell reprogramming
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cell Reprogramming Market, by Technology

  • 6.1. Introduction
  • 6.2. Episomal Reprogramming
  • 6.3. mRNA Reprogramming
  • 6.4. Sendai Virus-Based Reprogramming

7. Cell Reprogramming Market, by Application

  • 7.1. Introduction
  • 7.2. Research
  • 7.3. Therapeutic

8. Cell Reprogramming Market, by End-Use

  • 8.1. Introduction
  • 8.2. Biotechnology & Pharmaceutical Companies
  • 8.3. Hospitals & Clinics
  • 8.4. Research & Academic Institutes

9. Americas Cell Reprogramming Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cell Reprogramming Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cell Reprogramming Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ALSTEM Inc.
  • 2. Applied Biological Materials Inc.
  • 3. Axol Bioscience Ltd.
  • 4. Bit Bio Ltd.
  • 5. Bristol Myers Squibb Company
  • 6. CD Biosynsis
  • 7. Cell Reprogramming & Therapeutics LLC
  • 8. Cellular Reprogramming, Inc.
  • 9. Creative Bioarray
  • 10. DefiniGEN Limited
  • 11. Fujifilm LImited
  • 12. Lonza AG
  • 13. Merck KGaA
  • 14. Mogrify Limited
  • 15. REPROCELL Inc.
  • 16. Stemnovate Limited
  • 17. Takara Bio Inc.
  • 18. Thermo Fisher Scientific, Inc.
  • 19. TOKIWA-Bio inc.,
  • 20. Allele Biotechnology and Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. CELL REPROGRAMMING MARKET RESEARCH PROCESS
  • FIGURE 2. CELL REPROGRAMMING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CELL REPROGRAMMING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CELL REPROGRAMMING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELL REPROGRAMMING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL REPROGRAMMING MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY EPISOMAL REPROGRAMMING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY MRNA REPROGRAMMING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY SENDAI VIRUS-BASED REPROGRAMMING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. CELL REPROGRAMMING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. CELL REPROGRAMMING MARKET, FPNV POSITIONING MATRIX, 2023